<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Type 2 <z:hpo ids='HP_0000819'>diabetes mellitus</z:hpo> is associated with a specific pattern of plasma <z:chebi fb="23" ids="18059">lipid</z:chebi> and <z:chebi fb="1" ids="6495">lipoprotein</z:chebi> abnormalities </plain></SENT>
<SENT sid="1" pm="."><plain><z:chebi fb="23" ids="18059">Lipid</z:chebi> goals are often not attained with <z:chebi fb="0" ids="35664">statins</z:chebi> alone, and combination <z:chebi fb="23" ids="18059">lipid</z:chebi>-lowering strategies may need to be considered in an attempt to further reduce the residual cardiovascular risk </plain></SENT>
<SENT sid="2" pm="."><plain>Combination therapy utilizes various classes of <z:chebi fb="23" ids="18059">lipid</z:chebi>-lowering medications with different mechanisms of action and different effects on <z:chebi fb="23" ids="18059">lipid</z:chebi> levels </plain></SENT>
<SENT sid="3" pm="."><plain>Clinical trial data support the efficacy of combining <z:chebi fb="0" ids="35664">statins</z:chebi> with fibrates, niacin, <z:chebi fb="0" ids="49040">ezetimibe</z:chebi> (cholesterol absorption inhibitor) and colesevelam (<z:chebi fb="0" ids="3098">bile acid</z:chebi> sequestrant) with the caveat that there are insufficient clinical trial data to show a further robust benefit on cardiovascular outcomes </plain></SENT>
<SENT sid="4" pm="."><plain>Of the different combination therapy options to potentiate <z:chebi fb="1" ids="47774">low-density lipoprotein cholesterol</z:chebi> lowering in combination with a <z:chebi fb="0" ids="35664">statin</z:chebi>, colesevelam provides additional beneficial effects by further reducing <z:chebi fb="0" ids="35143">hemoglobin</z:chebi> A1c levels in Type 2 <z:hpo ids='HP_0000819'>diabetes mellitus</z:hpo> </plain></SENT>
</text></document>